Showing results (31-40 of 63) with videos related to
Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|October 15, 2008
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trialsAnne-Geneviève Marcelin, Philippe Flandre, Jean-Michel Molina, et al.Antiviral Therapy|January 24, 2012
Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohortFaroudy Boufassa, Cécile Goujard, Jean-Paul Viard, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 25, 2005
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073)Diane Descamps, Véronique Joly, Philippe Flandre, et al.The Journal of Antimicrobial Chemotherapy|January 17, 2009
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patientsDiane Descamps, Sidonie Lambert-Niclot, Anne-Geneviève Marcelin, et al.AIDS Research and Human Retroviruses|August 2, 2016
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective StudyOlivia Senard, Charles Burdet, Benoit Visseaux, et al.The Journal of Antimicrobial Chemotherapy|March 3, 2012
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patientsCharlotte Charpentier, Lucile Larrouy, Benoit Visseaux, et al.The Journal of Antimicrobial Chemotherapy|June 21, 2014
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assayCharlotte Charpentier, Marion Choquet, Véronique Joly, et al.Journal of Lipid Research|January 10, 2015
Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAARTPetra El Khoury, Mathilde Ghislain, Elise F Villard, et al.The Patient|March 27, 2015
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialJason Brunetta, Santiago Moreno Guillén, Andrea Antinori, et al.AIDS (London, England)|August 5, 2010
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimenConstance Delaugerre, Isabelle Charreau, Josephine Braun, et al.Pageof 7